SG11201803903YA - Combination therapy for cancer - Google Patents
Combination therapy for cancerInfo
- Publication number
- SG11201803903YA SG11201803903YA SG11201803903YA SG11201803903YA SG11201803903YA SG 11201803903Y A SG11201803903Y A SG 11201803903YA SG 11201803903Y A SG11201803903Y A SG 11201803903YA SG 11201803903Y A SG11201803903Y A SG 11201803903YA SG 11201803903Y A SG11201803903Y A SG 11201803903YA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- international
- indiana
- indianapolis
- company
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562267462P | 2015-12-15 | 2015-12-15 | |
| PCT/US2016/065503 WO2017105982A1 (fr) | 2015-12-15 | 2016-12-08 | Polythérapie contre le cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201803903YA true SG11201803903YA (en) | 2018-06-28 |
Family
ID=57590897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201803903YA SG11201803903YA (en) | 2015-12-15 | 2016-12-08 | Combination therapy for cancer |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20180228795A1 (fr) |
| EP (1) | EP3389660B1 (fr) |
| JP (1) | JP6359197B2 (fr) |
| KR (1) | KR20180081580A (fr) |
| CN (1) | CN108472293A (fr) |
| AU (1) | AU2016370297A1 (fr) |
| BR (1) | BR112018011203A2 (fr) |
| CA (1) | CA3005358A1 (fr) |
| EA (1) | EA201891005A1 (fr) |
| HK (1) | HK1254687A1 (fr) |
| IL (1) | IL259097A (fr) |
| MX (1) | MX2018007225A (fr) |
| NZ (1) | NZ742470A (fr) |
| SG (1) | SG11201803903YA (fr) |
| WO (1) | WO2017105982A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201402277D0 (en) | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8850801A1 (es) * | 2008-12-17 | 2010-07-27 | Lilly Co Eli | Compuestos útiles para inhibir chk1 |
| RU2017127088A (ru) * | 2010-11-16 | 2019-02-04 | Эррэй Биофарма Инк. | Комбинация ингибиторов чекпойнт-киназы 1 и ингибиторов киназы wee 1 |
| JO3003B1 (ar) * | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
| CA2860665A1 (fr) * | 2012-01-05 | 2013-07-11 | Dana-Farber Cancer Institute, Inc. | Procedes de traitement du cancer |
-
2016
- 2016-12-08 CN CN201680073762.1A patent/CN108472293A/zh active Pending
- 2016-12-08 MX MX2018007225A patent/MX2018007225A/es unknown
- 2016-12-08 US US15/513,189 patent/US20180228795A1/en not_active Abandoned
- 2016-12-08 EP EP16816563.7A patent/EP3389660B1/fr active Active
- 2016-12-08 SG SG11201803903YA patent/SG11201803903YA/en unknown
- 2016-12-08 WO PCT/US2016/065503 patent/WO2017105982A1/fr active Application Filing
- 2016-12-08 AU AU2016370297A patent/AU2016370297A1/en not_active Abandoned
- 2016-12-08 JP JP2017538245A patent/JP6359197B2/ja not_active Expired - Fee Related
- 2016-12-08 CA CA3005358A patent/CA3005358A1/fr not_active Abandoned
- 2016-12-08 KR KR1020187016468A patent/KR20180081580A/ko not_active Application Discontinuation
- 2016-12-08 EA EA201891005A patent/EA201891005A1/ru unknown
- 2016-12-08 NZ NZ74247016A patent/NZ742470A/en not_active IP Right Cessation
- 2016-12-08 BR BR112018011203A patent/BR112018011203A2/pt not_active Application Discontinuation
-
2018
- 2018-05-02 IL IL259097A patent/IL259097A/en unknown
- 2018-10-25 HK HK18113669.3A patent/HK1254687A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018007225A (es) | 2018-08-01 |
| WO2017105982A1 (fr) | 2017-06-22 |
| KR20180081580A (ko) | 2018-07-16 |
| AU2016370297A1 (en) | 2018-05-24 |
| EA201891005A1 (ru) | 2018-12-28 |
| IL259097A (en) | 2018-06-28 |
| NZ742470A (en) | 2019-09-27 |
| JP2018502873A (ja) | 2018-02-01 |
| BR112018011203A2 (pt) | 2018-11-21 |
| EP3389660B1 (fr) | 2019-10-16 |
| HK1254687A1 (zh) | 2019-07-26 |
| JP6359197B2 (ja) | 2018-07-18 |
| US20180228795A1 (en) | 2018-08-16 |
| CA3005358A1 (fr) | 2017-06-22 |
| EP3389660A1 (fr) | 2018-10-24 |
| CN108472293A (zh) | 2018-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201805872SA (en) | Chimeric antigen receptors targeting epidermal growth factor receptor variant iii | |
| SG11201811225RA (en) | Ar+ breast cancer treatment methods | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201810268YA (en) | Combination therapy with notch and pd-1 or pd-l1 inhibitors | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201803915UA (en) | Echinomycin formulation, method of making and method of use thereof | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201810940XA (en) | Methods of treating pancreatic cancer | |
| SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201803643TA (en) | Virulence attenuated bacteria for treatment of malignant solid tumors |